Hal Allergy

Executive Summary

HAL Allergy is a top European developer, producer, and distributor of allergen immunotherapies for allergic diseases. With a portfolio covering subcutaneous and sublingual products and a pipeline targeting future treatments, the company leverages its Leiden Bio Science Park location for innovation. Its focus on both treatment and prevention positions it as a key player in the allergy biologics space.

Upcoming Catalysts (preview)

• Q3 2026EMA approval for sublingual grass pollen immunotherapy tablet70% success
• H2 2026Phase 3 top-line data for house dust mite allergy vaccine65% success
• 2026Strategic partnership with a US biopharma for North American commercialization50% success